Drug profile · INN
tofacitinib citrate
XELJANZ INITIAL APPROVAL
tofacitinib citrate (XELJANZ INITIAL APPROVAL) is a janus kinase (jak) inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tofacitinib citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 16
- Data quality
- 0.84
Quick answer
tofacitinib citrate (XELJANZ INITIAL APPROVAL) is a janus kinase (jak) inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Janus Kinase (JAK) inhibitor
Primary target: Janus Kinase (JAK)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is tofacitinib citrate?
tofacitinib citrate (XELJANZ INITIAL APPROVAL) is a janus kinase (jak) inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tofacitinib citrate?
XELJANZ INITIAL APPROVAL is a marketed brand name for tofacitinib citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tofacitinib citrate?
tofacitinib citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.